← Back to Search

Small Molecule

PRLX 93936 for Multiple Myeloma

Phase 1 & 2
Waitlist Available
Led By Paul Richardson, MD
Research Sponsored by Prolexys Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRLX 93936Experimental Treatment1 Intervention
PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRLX 93936
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Prolexys PharmaceuticalsLead Sponsor
1 Previous Clinical Trials
37 Total Patients Enrolled
Paul Richardson, MDPrincipal InvestigatorDana-Farber Cancer Institute
11 Previous Clinical Trials
802 Total Patients Enrolled
10 Trials studying Multiple Myeloma
651 Patients Enrolled for Multiple Myeloma
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top